Efavirenz (SUSTIVA) expanded access begins October 1
- PMID: 11364689
Efavirenz (SUSTIVA) expanded access begins October 1
Abstract
AIDS: Efavirenz (SUSTIVA, formerly DMP 266), is being made available to AIDS patients who are failing or are intolerant of their current regimen, and who have no other options available. Patients must have a CD4 count less than or equal to 50 within the last 90 days. Excluded concomitant medications and other restrictions are provided. Efavirenz should be used with at least one other antiviral to which the patient has not been exposed, and the failing regimen should be changed entirely. Patients may also be receiving treatment on other expanded access programs. Efavirenz will be provided at no charge, but patients may have to pay for blood work and any other expenses.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials